PA-082 is a selective PPAR-gamma modulator that functions as a partial agonist. PA-082 causes partial recruitment of SRC1, TIF2, SRC3 and full recruitment of PGC1-alpha to PPAR-gamma ligand-binding domain. PA-082 prevents triglyceride accumulation during de novo adipogenesis and antagonizes Rosiglitazone (HY-17386)-induced lipid accumulation. PA-082 potentiates insulin-stimulated glucose uptake in adipocytes and protects against TNFalpha-induced insulin resistance. PA-082 can be used for the research of type 2 diabetes[1].
Molekulargewicht:
542.68
CAS Nummer:
[95520-87-9]
Formel:
C33H38N2O5
Target-Kategorie:
PGC-1alpha,PPAR
Anwendungsbeschreibung:
MCE Product type: Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
